Moon face

Symptoms and causes

Moon face is often associated with Cushing's syndrome or steroid treatment (especially corticosteroids), which has led to it being known as Cushingoid facies.

Moon face is a type of corticosteroid-induced lipodystrophy along with "buffalo hump", which in one study occurred in 47% of the 820 patients. Moon face is among the most frequently reported adverse events of systemic glucocorticoids, along with insomnia (58%), mood disturbances (50%), and hyperphagia (49%).

Another long-term study of 88 patients on prednisone showed that lipodystrophy, such as moon face, was the most frequent adverse event, experienced by 63% of patients.

Incidence

The risk for moon face increases with higher doses and longer time on steroid treatment. One study showed an increased risk in women, those younger than 50 years of age, and those with a high initial BMI.

Complications

This change in facial appearance can be very distressing to patients taking steroids. Later studies of the 88 patients showed that those who had lipodystrophy had a greater risk for metabolic syndrome characteristics such as increased blood pressure, higher plasma concentrations of fasting glucose, triglycerides, and total cholesterol, along with lower HDL-cholesterol.

Treatment

Cessation of steroid therapy or treatment of the cause of Cushing's syndrome causes moon face to slowly decrease and eventually vanish. One study proposed that limiting calories could decrease the risk of corticosteroid-induced lipodystrophy.

References

References

1. (2009-09-07). "Moon facies - definition from". Biology-Online.org.
2. (29 August 2012). "Iatrogenic Cushing's syndrome with inhaled steroid plus antidepressant drugs.". Multidisciplinary Respiratory Medicine.
3. Wilkins, L.W.. (2008). "Nurse's Five-minute Clinical Consult: Signs and symptoms". Wolters Kluwer Health/Lippincott Williams & Wilkins.
4. "Moon Facies: Causes and Treatment". webmd.com.
5. (2011). "Goldman's Cecil Medicine". Elsevier Saunders.
6. (January 2016). "Cushing's disease: a multidisciplinary overview of the clinical features, diagnosis, and treatment". Journal of Medicine and Life.
7. (2001). "Oral Diagnosis, Oral Medicine, and Treatment Planning". B.C. Decker.
8. (December 2015). "Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug. A cross-sectional online survey of 820 patients". Clinical Rheumatology.
9. (July 2007). "Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion". The British Journal of Dermatology.
10. (October 2007). "Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study". Journal of the American Academy of Dermatology.
11. (July 2015). "The man-in-the-moon face: a qualitative study of body image, self-image and medication use in systemic lupus erythematosus". Rheumatology.
12. (July 2007). "Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome". Rheumatology.
13. (May 2007). "[Systemic corticosteroid therapy: patients' adherence to dietary advice and relationship between food intake and corticosteroid-induced lipodystrophy]". La Revue de Médecine Interne.